Akoya Biosciences - AKYA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $7.25
  • Forecasted Upside: 207.20%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$2.36
▲ +0.13 (5.83%)

This chart shows the closing price for AKYA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Akoya Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AKYA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AKYA

Analyst Price Target is $7.25
▲ +207.20% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Akoya Biosciences in the last 3 months. The average price target is $7.25, with a high forecast of $10.00 and a low forecast of $4.00. The average price target represents a 207.20% upside from the last price of $2.36.

This chart shows the closing price for AKYA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 contributing investment analysts is to moderate buy stock in Akoya Biosciences. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/31/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/31/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/29/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/27/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/26/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/24/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/21/2024Craig HallumInitiated CoverageBuy$7.50Low
6/3/2024Morgan StanleyLower TargetOverweight ➝ Overweight$8.00 ➝ $4.00Low
5/14/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$10.00 ➝ $6.00Low
5/14/2024BTIG ResearchLower TargetBuy ➝ Buy$9.00 ➝ $6.00Low
3/6/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$12.00 ➝ $10.00Low
3/5/2024UBS GroupBoost TargetBuy ➝ Buy$7.00 ➝ $7.50Low
3/5/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$10.00Low
12/14/2023GuggenheimInitiated CoverageNeutralLow
11/13/2023Piper SandlerLower TargetOverweight ➝ Overweight$11.00 ➝ $8.00Low
11/13/2023StephensLower TargetOverweight ➝ Overweight$14.00 ➝ $9.00Low
10/24/2023Morgan StanleyLower TargetOverweight ➝ Overweight$15.00 ➝ $8.00Low
10/16/2023Piper SandlerLower TargetOverweight ➝ Overweight$14.00 ➝ $11.00Low
10/12/2023UBS GroupLower TargetBuy ➝ Buy$12.00 ➝ $7.00Low
8/9/2023StephensLower Target$16.00 ➝ $14.00Low
8/8/2023BTIG ResearchLower Target$14.00 ➝ $11.00Low
8/8/2023StephensReiterated RatingOverweight ➝ Overweight$16.00Low
8/8/2023Morgan StanleyLower TargetOverweight ➝ Overweight$16.00 ➝ $15.00Low
3/21/2023StephensReiterated RatingOverweight$16.00Low
3/13/2023Piper SandlerLower Target$17.00 ➝ $13.00Low
3/8/2023Morgan StanleyLower TargetOverweight$18.00 ➝ $17.00Low
2/2/2023UBS GroupInitiated CoverageBuy$14.00Low
11/15/2022BTIG ResearchLower Target$18.00N/A
11/3/2022Capital One FinancialInitiated CoverageOverweight$19.00Low
10/5/2022StephensInitiated CoverageOverweight$16.00Low
8/17/2022Piper SandlerBoost TargetOverweight$14.00 ➝ $17.00Low
8/15/2022BTIG ResearchBoost Target$20.00Low
7/19/2022BTIG ResearchSet Target$18.00N/A
6/22/2022BTIG ResearchInitiated CoverageBuy$16.00Low
5/15/2022Piper SandlerLower TargetNA$18.00 ➝ $14.00High
3/17/2022Piper SandlerLower TargetOverweight$23.00 ➝ $18.00Low
3/15/2022Morgan StanleyLower TargetOverweight$20.00 ➝ $19.00High
2/15/2022Morgan StanleyLower TargetOverweight$24.00 ➝ $20.00Low
5/11/2021JPMorgan Chase & Co.Initiated CoverageOverweight$23.00High
5/11/2021Piper SandlerInitiated CoverageOverweight$28.00High
5/11/2021Morgan StanleyInitiated CoverageOverweight$26.00High
(Data available from 6/23/2019 forward)

News Sentiment Rating

1.27 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/26/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2023
  • 4 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
1/25/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/24/2024
  • 10 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/25/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/24/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/24/2024
  • 6 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2024

Current Sentiment

  • 6 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Akoya Biosciences logo
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Read More

Today's Range

Now: $2.36
Low: $2.28
High: $2.60

50 Day Range

MA: $2.99
Low: $1.94
High: $4.48

52 Week Range

Now: $2.36
Low: $1.88
High: $7.68

Volume

929,971 shs

Average Volume

304,459 shs

Market Capitalization

$116.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Akoya Biosciences?

The following Wall Street sell-side analysts have issued research reports on Akoya Biosciences in the last year: BTIG Research, Canaccord Genuity Group Inc., Craig Hallum, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Stephens, and UBS Group AG.
View the latest analyst ratings for AKYA.

What is the current price target for Akoya Biosciences?

8 Wall Street analysts have set twelve-month price targets for Akoya Biosciences in the last year. Their average twelve-month price target is $7.25, suggesting a possible upside of 207.2%. JPMorgan Chase & Co. has the highest price target set, predicting AKYA will reach $10.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $4.00 for Akoya Biosciences in the next year.
View the latest price targets for AKYA.

What is the current consensus analyst rating for Akoya Biosciences?

Akoya Biosciences currently has 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AKYA.

What other companies compete with Akoya Biosciences?

How do I contact Akoya Biosciences' investor relations team?

The company's listed phone number is 855-896-8401 and its investor relations email address is [email protected]. The official website for Akoya Biosciences is www.akoyabio.com. Learn More about contacing Akoya Biosciences investor relations.